Highlights•Studies have shown that high PTH was associated with NAFLD/NASH, although the results from existing studies are inconsistent.•Using systematic review, 10 and 4 studies reported the association of PTH with NAFLD and NASH, respectively.•The meta-analysis suggested that high PTH can be a marker of NAFLD.•The meta-analysis also revealed that high PTH tended to be associated… Continue reading High #parathyroid hormone level as a marker of non-alcoholic #fatty #liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
Tag: NASH
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
BACKGROUNDPegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of pegozafermin in patients with biopsy-proven noncirrhotic NASH are not well established.METHODSIn this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial,… Continue reading Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial
Management of nonalcoholic steatohepatitis (NASH) is a currently unmet clinical need. Digital therapeutics (DTx) is an emerging class of medicine that delivers evidence-based therapeutic interventions. The current study was aimed at investigating the efficacy of DTx in patients with NASH.METHODS: We conducted a multicenter, single-arm, 48-week trial in 20 patients with biopsy-confirmed NASH. All patients received… Continue reading Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial
Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study
Background and AimsWhile heavy alcohol use consistently associates with liver disease, the effects of non-heavy alcohol consumption are less understood. We aimed to investigate the relationship between non-heavy alcohol use and chronic liver disease.MethodsThis cross-sectional study included 2629 current drinkers in the Framingham Heart Study who completed alcohol use questionnaires and transient elastography. We defined… Continue reading Non-heavy alcohol use associates with liver fibrosis and ‘nonalcoholic’ steatohepatitis in the Framingham Heart Study
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Patients with NASH, NAS≥4, and F≥2 (Fibro-NASH) are at highest risk for disease progression.➢Patients with Fibro-NASH are targeted for proof-of-concept NASH trials.➢MRI-PDFF and MR elastography are the most common primary and secondary endpoints in NASH trials, respectively.➢To identify Fibro-NASH, the MRI-AST (MAST) score was created based on these MRI techniques.➢The MAST score was proven to… Continue reading MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
•EDP-305 is an oral farnesoid X receptor (FXR) agonist being developed to treat nonalcoholic steatohepatitis (NASH).•In a randomized, placebo-controlled study, 12-week study, EDP-305 reduced ALT levels and MRI-PDFF•These results support further development of EDP-305 in patients with NASH with longer term studies. ABSTRACTBackground & AimsEDP-305 is an oral farnesoid X receptor (FXR) agonist under development… Continue reading EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions that underlie the development of life-threatening cirrhosis, liver failure and liver cancer. Chronic necro-inflammation is a critical factor in development of NASH, yet the cellular and molecular mechanisms of immune dysregulation in this disease are poorly understood. Here, using single-cell transcriptomic analysis,… Continue reading XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis
#Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis
We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.. ..The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased… Continue reading #Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis
A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to… Continue reading A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis
2 Medical News 